[Asia Economy Reporter Lee Chun-hee] Cha Biotech announced on the 29th that it will participate in the "2023 JP Morgan Healthcare Conference" to be held in San Francisco, USA, from the 9th to the 12th of next month (local time).
The JP Morgan Healthcare Conference is the world's largest healthcare investment event, with over 1,500 pharmaceutical and biotech companies from more than 50 countries participating annually. Cha Biotech plans to introduce its current focused pipeline through one-on-one meetings with overseas companies and discuss technology transfer, joint development, and investment attraction.
Cha Biotech plans to introduce its current focus areas, including the anticancer immune cell therapy 'CBT101,' the cell therapy for chronic low back pain caused by degenerative lumbar intervertebral discs 'CordSTEM-DD,' the cell therapy for ovarian dysfunction 'CordSTEM-POI,' and the Parkinson's disease cell therapy 'CBT-NPC.' It is reported that meetings with more than 30 global pharmaceutical companies are planned.
Yang Eun-young, Head of Strategic BD at Cha Biotech Group, said, "Many global pharmaceutical and biotech companies are showing interest in Cha Biotech's cell therapy pipeline," adding, "We will actively promote Cha Biotech's core technologies and the development status of major cell therapies in overseas markets to expand business opportunities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
